Pieris Pharmaceuticals Inc expected to post a loss of 26 cents a share - Earnings Preview

Palvella Therapeutics

02/08/2021 16:41

* Pieris Pharmaceuticals Inc  PIRS.OQ   PIRS.O  is expected
to show a fall in quarterly revenue when it reports results on
August 4. 
* The Boston, Massachusetts-based company is expected to report 
 a 81.5% decrease in revenue to $2.076 million from $11.25
million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Pieris Pharmaceuticals
Inc is for a loss of 26 cents per share. For the same quarter
last year, the company reported a loss of 9 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Pieris
Pharmaceuticals Inc is $8.5​, about 59.1% above​ its last
closing price of $3.48. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.17       -0.17      -0.07     Beat    58.8
 Dec. 31 2020              -0.24      -0.26     Missed  -9.9
 Sep. 30 2020  -0.14       -0.13      -0.26     Missed  -99.7​
 Jun. 30 2020  -0.18       -0.17      -0.09     Beat    47.6
 Mar.          -0.19​      -0.17      -0.07     Beat    57.8​
 31​ 2020​                                              
 Dec. 31 2019  -0.23       -0.28      -0.06     Beat    78.4​
 Sep. 30 2019  -0.23       -0.23      -0.05     Beat    78.2
 Jun. 30 2019  -0.19       -0.20      -0.24     Missed  -19.4
 This summary was machine generated August 2 at 15:41 GMT.  All
figures in US dollars unless otherwise stated